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Although vesicular stomatitis virus (VSV) neurovirulence and pathogenicity in rodents have been well studied, little is known about VSV
pathogenicity in non-human primates. To address this question, we measured VSV viremia, shedding, and neurovirulence in macaques. Following
intranasal inoculation, macaques shed minimal recombinant VSV (rVSV) in nasal washes for 1 day post-inoculation; viremia was not detected.
Following intranasal inoculation of macaques, wild type (wt) VSV, rVSV, and two rVSV-HIV vectors showed no evidence of spread to CNS
tissues. However, macaques inoculated intrathalamically with wt VSV developed severe neurological disease. One of four macaques receiving
rVSV developed clinical and histological signs similar to the wt group, while the remaining three macaques in this group and all of the macaques
in the rVSV-HIV vector groups showed no clinical signs of disease and reduced severity of histopathology compared to the wt group. The
implications of these findings for rVSV vaccine development are discussed.
© 2006 Elsevier Inc. All rights reserved.Keywords: Vesicular stomatitis virus; Pathogenicity; Neurovirulence; Viral vectors; Non-human primates; HIV vaccine; IntrathalamicIntroduction
Vesicular stomatitis virus (VSV) is a non-segmented, single-
stranded, negative-sense RNA virus of the family Rhabdoviri-
dae. Recombinant VSV (rVSV) is a promising vaccine vector
because its simple genome can accommodate multiple foreign
genes, it does not undergo either recombination or integration
into host cell DNA, and it grows to high titers in many different
cell types, facilitating vaccine manufacture. Moreover, rVSV
generates potent cellular and humoral immune responses to
abundantly expressed foreign antigens (for reviews, see Roberts
and Rose, 1998; Rose and Whitt, 2001). Recombinant VSV-⁎ Corresponding author. Fax: +1 845 602 4977.
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doi:10.1016/j.virol.2006.10.026based vectors have been investigated preclinically as vaccine
candidates for such infectious diseases as influenza virus
(Roberts et al., 1999), respiratory syncytial virus (Kahn et al.,
2001), measles virus (Schlereth et al., 2000, 2003), papilloma-
virus (Reuter et al., 2002; Roberts et al., 2004), severe acute
respiratory syndrome-coronavirus (Kapadia et al., 2005), Ebola
and Marburg viruses (Jones et al., 2005), as well as human
immunodeficiency virus [HIV] (Egan et al., 2004; Rose et al.,
2000, 2001). The efficacy of rVSV vectors was demonstrated
for HIV vaccine candidates when macaques immunized with
rVSVs expressing SIV Gag and HIV Env proteins were
protected from disease following challenge with pathogenic
SIV/HIV hybrid (SHIV) 89.6P (Egan et al., 2004; Rose et al.,
2001). A more recent study has demonstrated enhanced
immunogenicity and efficacy in macaques following a DNA-
prime/rVSV-boost vaccination regimen (Egan et al., 2005).
Based on these promising results, we chose to develop rVSVs
expressing HIV proteins for clinical evaluation.
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Mudd-Summers isolates of wild type (wt) Indiana serotype
VSV (VSVIN) that were first adapted through multiple
passages in cultured cells. A reverse genetics system allowed
rescue of infectious virus from cDNA (Lawson et al., 1995;
Whelan et al., 1995). The prototypic VSVIN cDNA clone was
modified to allow foreign gene expression (Schnell et al.,
1996a,b). To investigate immunogenicity and efficacy in an
SHIV challenge model, separate rVSVIN vectors were
engineered that encoded SIV gag and HIV env genes. To
circumvent the high level of neutralizing antibodies directed
against the VSV surface glycoprotein (G), rVSV vectors
encoding SIV Gag and HIV Env were modified by exchanging
the Indiana G gene with G genes of other vesiculovirus
serotypes (Rose et al., 2000, 2001). Vectors incorporating
heterologous glycoproteins were used to boost macaques that
had been primed with G-Indiana serotype vectors (Egan et al.,
2004; Rose et al., 2001). Following a high dose SHIV
challenge, all vaccinated macaques were able to control the
infection, maintain low viral loads and normal CD4 counts,
and remain free from disease 5 years post-challenge (Egan et
al., 2004; Rose et al., 2001).
VSV is a natural pathogen of livestock that causes disease in
cattle, swine, and horses marked by febrile illness and vesicular
lesions of the lips, mouth, nose, teats, and hooves that usually
resolve in a few weeks without fatality [reviewed in Letchworth
et al., 1999]. Transmission occurs through direct contact
between infected animals, and it is thought that abrasion or
scarification of skin or mucosal epithelium increases the virus's
ability to infect at these sites (Letchworth et al., 1999).
Furthermore, there is evidence that biting insects may serve as
vectors for VSV (Brandly and Hanson, 1957; Letchworth et al.,
1999; Tesh and Johnson, 1975).
Documented cases of human VSV infections are rare and
tend to occur in agricultural, veterinary, and laboratory
workers or in areas where VSV infection is endemic in its
natural hosts (Brandly and Hanson, 1957; Brody et al., 1967;
Fellowes et al., 1955; Ferris et al., 1955; Fields and Hawkins,
1967; Hanson et al., 1950; Heiny, 1945; Johnson et al., 1966;
Reif et al., 1987; Webb et al., 1987). Human infection is
typically subclinical or results in a mild flu-like disease that is
self-limited (Brandly and Hanson, 1957; Fellowes et al., 1955;
Patterson et al., 1958; Tesh and Johnson, 1975). While
encephalitis is not a feature of VSV natural infection
(Letchworth et al., 1999), VSV neurotropism and neuroviru-
lence (NV) have been demonstrated in rodent models (Bi
et al., 1995; Fournier et al., 1988; Fultz et al., 1981; Huneycutt
et al., 1994; Miyoshi et al., 1971; Plakhov et al., 1995; Reiss
et al., 1998; Sur et al., 2003; van den Pol et al., 2002).
Furthermore, early studies involving experimental intracerebral
inoculation of rhesus and cynomolgus macaques (Olitsky et al.,
1934), horses, cattle, and sheep (Frank et al., 1945) also
indicated the NV potential of VSV. Recently, Chandipura virus,
a related vesiculovirus, was associated with an outbreak of
encephalitis in children in India (Rao et al., 2004), although the
etiologic role of Chandipura virus in human epidemic
encephalitis has been questioned (John, 2004).Replication competent viral vaccines have historically been
subjected to NV testing, which usually involves direct
inoculation of virus into the central nervous system of
susceptible non-human primates (NHP). NHP NV tests have
been developed for poliovirus (Nathanson and Horn, 1992;
Wood and Macadam, 1997), measles virus (Sharova et al.,
1979; Yamanouchi et al., 1976), mumps virus (Levenbook et
al., 1979; Maximova et al., 1996; Rubin et al., 1999), and
yellow fever virus (Levenbook et al., 1987; Marchevsky et
al., 2003; WHO, 1998). In most cases, vaccine strains are
inoculated directly into NHP brains and compared to
reference controls. Clinical parameters are measured for a
period of up to 30 days, at which time brain and spinal cord
tissues are analyzed histologically for virus-induced lesions.
The NHP NV test for yellow fever vaccine involves scoring
systems for both clinical signs as well as histological lesions
in CNS tissue; acceptability is based on a comparison of
clinical and histological scores to those of a reference control
(Levenbook et al., 1987). Similarly, a histological lesion
scoring system is used to determine acceptability of mumps
vaccine lots following direct inoculation into the thalamus of
NHPs (Maximova et al., 1996).
The development of rVSV vaccines for human use requires
appropriate attenuation to remove vector-associated pathogen-
esis. A previous study in mice indicated that a low dose of the
tissue culture-adapted wt VSVIN San Juan isolate inoculated
intranasally caused weight loss, paralysis, and death, while a
similar dose of rVSVIN caused only weight loss in mice (Roberts
et al., 1998). Similarly, an rVSVIN vector encoding an influenza
virus hemagglutinin gene caused a transient weight loss
following intranasal (IN) inoculation of mice at higher doses
(Roberts et al., 1999). An rVSV vector containing a truncation in
G (labeled CT1) did not cause weight loss following IN
inoculation of mice (Roberts et al., 1999), indicating the ability
to decrease vector pathogenicity with attenuating mutations. The
well-established ability of VSV to cause NV in rodents
following IN inoculation (Bi et al., 1995; Huneycutt et al.,
1994; Lundh et al., 1987; Olitsky et al., 1934; Reiss et al., 1998;
Sabin and Olitsky, 1937; Sur et al., 2003) and the weight loss
observed in mice following IN inoculation with the rVSVIN
vector (Roberts et al., 1998, 1999) indicate that rodents are
highly permissive for VSV infection. Since more than 150
rhesus macaques have been inoculated both intranasally and
intramuscularly with high doses of rVSVIN vectors without
adverse clinical events [(Egan et al., 2004; Rose et al., 2001), and
unpublished observations], we decided to assess our rVSV-HIV
variants for vector-associated pathogenicity in NHPs. In three
separate exploratory studies, we measured viremia, viral
shedding, and neuroinvasiveness following IN inoculation and
NV following intrathalamic (IT) inoculation. In each study,
macaques were inoculated with 107 PFU of virus, which is the
highest dose previously tested in preclinical NHP studies (Egan
et al., 2004, 2005). The neuroinvasiveness and NV studies were
modeled on the stringent NV tests used to characterize live
mumps virus and yellow fever virus vaccine preparations
(Levenbook et al., 1979, 1987; Marchevsky et al., 2003;
Maximova et al., 1996; Rubin et al., 1999; WHO, 1998).
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VSV shedding and lack of detectable viremia following IN
inoculation with rVSVIN
A pilot study was performed to measure viremia and
shedding of infectious virus following IN inoculation of
three rhesus macaques with 107 PFU of rVSVIN (Fig. 1A).
Blood and serum were collected pre-dose and then, along
with nasal washes and saliva, were collected every day for
the first 4 days following inoculation and at defined
intervals thereafter (see Materials and methods). Using a
standard plaque assay, infectious virus was observed in nasal
wash samples of all three inoculated macaques at day 1
(Table 1). Only one macaque (number 23) had a low level
(1–10 PFU/mL) of detectable infectious virus in its nasal
wash at day 2. No infectious virus was detected in nasal
wash samples from any macaques following day 2. The twoFig. 1. NHP safety study designs. (A) Rhesus macaque shedding study. The genome
and controls for the study are indicated. (B) Cynomolgus macaque NV and neuroinv
along with the dose per macaque, route of inoculation, the number of macaques p
cynomolgus macaque brain tissue and spinal cord sections collected at necropsy for h
covered by collected sections are also indicated.macaques (numbers 48 and 62) that had the highest titers of
virus in nasal wash samples at day 1 also shed low levels of
infectious virus (10–100 PFU/mL) in their saliva at day 1.
No virus was detected in saliva of the third macaque
(number 23) on day 1. Infectious virus was not detected in
saliva from any macaque following day 1. The unvaccinated
macaques served as negative controls for all samples at all
time points (Table 1).
In addition to viral shedding at mucosal surfaces, we assayed
plasma and peripheral blood mononuclear cells (PBMCs) for
the presence of infectious virus following IN inoculation.
Infectious virus was not detected in plasma or PBMCs of any
macaque post-inoculation, indicating the absence of detectable
viremia in vaccinated macaques.
Using a VSV neutralization assay, VSVIN-specific serum
antibodies were detected in all three vaccinated macaques by
day 14 (Table 2), indicating that a productive infection occurred
following IN inoculation.organization of the rVSVIN virus is depicted, and the dose, route of inoculation,
asiveness studies. The genome organization of each virus or vector is depicted,
er group, and the day of scheduled euthanasia. (C) Bars indicate sections of
istological analysis in the NVand neuroinvasiveness studies. Anatomical regions
Table 1
Shedding of infectious virus following IN inoculation of rhesus macaques
Group Macaque no. a Nasal wash Saliva
Day 1 Day 2 Day 3 Day 4 Day 1 Day 2 Day 3 Day 4
rVSVIN 23 +
b +/− − − − − − −
48 +++ − − − + − − −
62 +++ − − − + − − −
Control 31 − − − − − − − −
24 − − − − − − − −
a Macaques 23, 48, and 62 were inoculated IN with 107 PFU of rVSVIN. Macaques 31 and 24 were un-inoculated controls.
b Infectivity scale: −, no virus detected; +/−, 1–10 PFU/mL; +, 10–100 PFU/mL; ++, 100–1000 PFU/mL; +++, 1000–10,000 PFU/mL.
Table 3
Daily and group mean clinical scores for cynomolgus macaques inoculated IT
Group Macaque no. Clinical score a
Daily mean Group mean
39J.E. Johnson et al. / Virology 360 (2007) 36–49No evidence of neuroinvasion following IN inoculation
Cynomolgus macaques were inoculated IN on day 0 with
107 PFU of VSVIN as shown in Fig. 1B. Macaques were
clinically monitored for 21 days, at which time they were
subjected to euthanasia, necropsy, and tissue harvest. Group
mean clinical scores of macaques in all groups were ≤0.1 (out
of 4); the wt VSVIN and all rVSVIN groups were indistinguish-
able from the scores of the negative control group.
To assess neuroinvasiveness, brain and spinal cord tissues
were harvested at necropsy and analyzed by plaque assay,
real-time, quantitative RT-PCR, and histopathologic examina-
tion. No virus or viral RNA was detected in frontal cortex,
occipital cortex, olfactory bulb, CSF, or nasal turbinates from
any of the macaques at day 21. Furthermore, histopatholo-
gical analysis revealed that no treatment related lesions or
changes were present in the brains or spinal cords of
macaques given wt VSVIN or rVSVIN vectors compared
with the control macaques given PBS. These results indicate
that none of the rVSVIN vectors or even the wt VSVIN was
capable of spreading to the CNS following IN inoculation. To
demonstrate that the macaques inoculated IN with each virus
were productively infected, we measured anti-VSVIN neu-Table 2
Anti-VSVIN serum neutralization antibodies
Study Route Group Day Geometric mean
titer a
Shedding IN rVSVIN 8 <40
14 1040
22 1890
Control 22 <40
Neuroinvasiveness IN wt VSVIN 21 1522
rVSVIN 21 2167
rVSVIN-HIVGag5 21 1280
rVSVIN–CT1-HIVGag5 21 <40
PBS 21 <40
Neurovirulence IT wt VSVIN 8 226
rVSVIN 8
b 40
21 c 1280
rVSVIN-HIVGag5 21 4305
rVSVIN-CT1-HIVGag5 21 80
PBS 21 <40
a Titer expressed as reciprocal dilution required to neutralize 100 PFU VSV
(limit of detection=40).
b One macaque in this group was euthanized by day 8.
c Three macaques in this group survived 21 days.tralizing antibodies (Table 2). Macaques in the wt VSVIN,
rVSVIN, and rVSVIN-HIVGag5 groups all had neutralizing
antibodies in the range of 600–6000 (geometric mean titers
between 1280 and 2167, Table 2). Macaques in the rVSVIN-
CT1-HIVGag5 and PBS groups did not have detectable
neutralization titers.
Neurovirulence study clinical observations
Following IT inoculation with 107 PFU of virus, all four
macaques in the wt VSVIN group and one of four in the
rVSVIN backbone group were euthanized early because of
declining health status, which included head tilt, irregular
gait, tremors, and ataxia, signs consistent with neurological
disease (Table 3). The onset of these signs generally occurred
on day 6 or 7 post-inoculation. There were no significant
virus related clinical signs in the remaining macaques in thewt VSVIN 21545M
b 3 3
22212M b 3
22190F b 3
16739F b 3
rVSVIN 21733M 0 1
21725M 1
21789F 0
21392F b 3
rVSVIN-HIVGag5 19439M 0 0
22245M 0
21275F 0
21578F 0
rVSVIN-CT1-HIVGag5 22253M 0 0
22235M 0
21797F 0
21576F 0
PBS 21724M 0 1
22238M 0
22290F 3 c
21765F 0
a Clinical scores based on a scale of 0–4, see Materials and methods.
b Euthanized on day 8 post IT challenge and given a score of 4 for subsequent
days.
c Macaque had head tilt, lethargy, decreased activity, and bilateral pupil
dilation on days 1–21, which were considered secondary to the surgical
procedures (see Results).
Table 5
Genomic sequence results of viruses isolated from macaque brain tissue at day 8
Virus Macaque no. Sequence changes from input virus
wt VSVIN F16739F Q299R in G gene
F22212M No changes
F22190F No changes
F21545M Q496H, D1316N in L gene
rVSVIN F21392F No changes
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22290F, had a head tilt, lethargy, and bilateral pupil dilation
on days 1–21 (Table 3). Because the onset of these signs
occurred earlier than those in the wt or rVSVIN groups, and
because none of the other macaques in the control group
displayed similar signs, it was concluded that these clinical
features were procedure-related.
Detection of VSV in tissues from IT groups
At the time of necropsy, samples were taken from the frontal
and occipital cortices, as well as from CSF, and were assayed for
infectious VSV by plaque assay and for viral RNA by real-time
quantitative RT-PCR. All five macaques euthanized by day 8
had infectious virus in the frontal cortex, which was the brain
section most proximal to the injection site. Viral titers were
within the range of 102–107 PFU/g (Table 4). Similarly, viral
genomic RNA within the range of 106–1010 copies/g was
detected in the frontal cortex of all five of these macaques. None
of the five macaques euthanized by day 8 had infectious virus in
the occipital cortex, which was distal to the injection site.
However, three of the four macaques in the wt group did have
low levels (105 to 106 copies/g) of detectable viral RNA in their
occipital lobes. In addition, low levels of infectious virus
(56 PFU/mL) and viral genomes (5.8×105 copies/mL) were
detected in the CSF of one macaque in the wt group, F22190F
(Table 4). All other tissues and CSF from this group were
negative for infectious virus and viral genomes. Viruses
recovered from brain samples of macaques subjected to
euthanasia by day 8 were sequenced across their entire
genomes. Virus isolated from two out of four macaques in the
wt group had no mutations relative to the inoculum. Of the
viruses isolated from the remaining two wt-inoculated maca-
ques, one had a single amino acid substitution in G and the other
had two substitutions in L (Table 5). The virus isolated from the
one rVSVIN macaque euthanized by day 8 was found to contain
identical sequence relative to input virus (Table 5). Taken
together, these results suggest that the clinical outcomes in these
macaques were caused by the input viruses rather than by
selection mutants with increased NV potential.
For the remaining macaques in the rVSVIN group and all the
macaques in the rVSVIN-HIVGag5 and rVSVIN-CT1-HIVGag5
groups, no infectious virus or viral RNA was detected in anyTable 4
Viral loads in tissues from IT-inoculated cynomolgus macaques, day 8 post-inocula
Virus Macaque no. Plaque assay (log10 PFU/g tissue or mL
Frontal cortex b Occipital lobe b
wt VSVIN F22190F 6.74 –
c
F21545M 2.16 –
F22212M 2.87 –
F16739F 5.67 –
rVSVIN F21392F 5.21 –
a Viral loads were assayed for macaques in all groups; all of those that survived t
b Tissues collected during necropsy, CSF collected immediately prior to necropsy
c “–” indicates below the limit of detection of the assay (plaque assay=2 log10 PF
tissue and 5.3 log10 copies/mL of CSF).tissue sample collected at necropsy (day 21). Similarly, the
tissues from the PBS group of macaques were negative in both
assays.
To demonstrate that productive infections occurred in all
groups, including those with no clinical scores or detectable
virus, neutralizing antibodies were measured in the IT groups of
macaques (Table 2). All macaques that were euthanized by day
8 had low levels of neutralizing antibodies (geometric mean
titers between 40 and 230). All rVSVIN and rVSVIN-HIVGag5
macaques that survived to day 21 had neutralizing antibodies
between 600 and 6000 (geometric mean titers between 1280 and
4305). With the exception of one macaque that had an
undetectable neutralizing antibody titer, those in the rVSVIN-
CT1-HIVGag5 group had neutralizing antibody titers of 80–
160 (geometric mean=80).
Histopathological analysis of brain and spinal cord tissues
from macaques in IT groups
Slides of fixed brain and spinal cord tissues were
analyzed for histological changes. For each tissue section,
observed lesions were noted according to relative size,
number, and type (e.g., inflammatory, necrotic, perivascular,
periventricular). To summarize the histological findings, the
following scoring system was used to quantify the observed
lesion severities: 0=no lesions, 1=minimal, 2=moderate,
3=marked, 4=severe (Table 6). Macaques inoculated with
PBS had only minimal to moderate areas of malacia and
inflammation localized to the injection site, which indicated
tissue damage resulting from the needle. Macaque 22290F
(PBS), which had an average clinical score of 3 for the
length of the study (Table 3), displayed only needle track-
associated tissue damage (Table 6), which supported thetion a
CSF) RT-PCR (log10 copies/g tissue or mL CSF)
CSFb Frontal cortex Occipital lobe CSF
1.74 9.10 5.78 5.76
– 6.61 – –
– 8.40 5.05 –
– 8.64 5.01 –
– 6.66 – –
o day 21 had undetectable viral loads in both assays.
.
U/g of tissue and 1 log10 PFU/mL of CSF; RT-PCR assay=5 log10 copies/g of
Table 6
Summary of histopathological scores in brain tissue of cynomolgus macaques following IT inoculation
Virus Macaque no. Day a Brain section b Spinal cord section c
BG T C FC OC Mean Cerv Thor Lum Mean
wt VSVIN 22190F 8 4.0
d 3.0 2.0 2.0 2.0 2.6 NS e NS NS na f
22212M 8 4.0 4.0 4.0 2.0 2.0 3.2 2.0 2.0 0.0 1.3
16739F 8 2.0 3.0 2.0 1.0 1.0 1.8 0.0 0.0 0.0 0.0
21545M 8 2.0 3.0 2.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0
mean 3.0 3.3 2.5 1.3 1.3 2.3 g 0.7 0.7 0.0 0.5 h
rVSVIN 21392F 8 2.0 4.0 2.0 2.0 2.0 2.4 NS NS NS na
21733M 21 2.0 2.0 2.0 1.0 1.0 1.6 2.0 3.0 4.0 3.0
21789F 21 4.0 3.0 2.0 2.0 1.0 2.4 2.0 3.0 4.0 3.0
21725M 21 2.0 3.0 2.0 1.0 1.0 1.8 1.0 3.0 2.0 2.0
mean 2.5 3.0 2.0 1.5 1.3 2.1 g 1.7 3.0 3.3 2.7 g
rVSVIN-HIVGag5 19439M 21 2.0 1.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0
21275F 21 1.0 1.0 1.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0
22245M 21 1.0 1.0 0.0 1.0 1.0 0.8 2.0 1.0 2.0 1.7
21578F 21 2.0 4.0 2.0 1.0 1.0 2.0 1.0 2.0 3.0 2.0
mean 1.5 1.8 0.8 0.5 0.5 1.0 i 0.8 0.8 1.3 1.0 h
rVSVIN-CT1-HIVGag5 22253M 21 1.0 2.0 1.0 0.0 0.0 0.8 0.0 2.0 0.0 0.7
21797F 21 2.0 3.0 0.0 0.0 2.0 1.4 0.0 2.0 0.0 0.7
22235M 21 1.0 3.0 0.0 1.0 1.0 1.2 0.0 0.0 0.0 0.0
21576F 21 1.0 3.0 2.0 1.0 1.0 1.6 1.0 0.0 1.0 0.7
mean 1.3 2.8 0.8 0.5 1.0 1.3 i 0.3 1.0 0.3 0.5 h
PBS 21724M 21 1.0 1.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0
22290F 21 0.0 2.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0
22238M 21 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
21765F 21 0.0 1.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0
mean 0.3 1.0 0.0 0.0 0.0 0.3 i 0.0 0.0 0.0 0.0 h
a Day of euthanasia.
b Brain sections: BG, basal ganglia; T, thalamus; C, cerebellum; FC, frontal cortex; OC, occipital cortex (see Fig. 1C).
c Spinal cord sections: cerv, cervical; thor, thoracic; lum, lumbar (see Fig. 1C).
d Lesion severity scoring system: 0, no lesions; 1, minimal; 2, moderate; 3, marked; 4, severe.
e NS, no slide available.
f na, not applicable.
g P<0.01 vs. PBS.
h P<0.05 vs. rVSVIN.
i P≤0.05 vs. wt VSVIN.
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were no notable lesions in other tissue sections in the PBS
group (Fig. 2E, Table 6). Brain sections from macaques
inoculated with wt VSVIN showed moderate to severe
necrotizing meningoencephalitis characterized by malacia,
hemorrhage, choroiditis, loss of ependymal cells, and
moderate numbers of perivascular cuffs of mononuclear
cells (Fig. 2A). Macaques inoculated with rVSVIN had
lesions that were of similar severity to those in the wt
VSVIN group; however, the lesions in the rVSVIN macaques
were characterized by a predominant cellular inflammatory
response with fewer areas of malacia than in the wt VSVIN
inoculated macaques (Fig. 2B). The macaques in the
rVSVIN-HIVGag5 and rVSVIN-CT1-HIVGag5 groups had
lesions that were primarily inflammatory with minimal to
moderate severity (Figs. 2C, D, F, and Table 6). Statistical
analysis of the brain lesion scores (Table 6) revealed that the
wt VSVIN and rVSVIN groups were significantly greater thanthose of the PBS control group (p<0.01) whereas the
rVSVIN-HIVGag5 and rVSVIN-CT1-HIVGag5 group scores
did not differ significantly from those of the PBS control
group.
It is noteworthy that the wt VSVIN inoculated macaques
generally had fewer, less severe lesions in their spinal cords than
the macaques in the rVSVIN group (Fig. 3 and Table 6). The
mean severity score for spinal cord lesions in the wt VSVIN
group (Fig. 3A) was 0.5 (minimal), while the mean score for the
rVSVIN group (Fig. 3B) was 2.7 (marked). Macaques in both
HIVGag5 vector groups had spinal cord lesions that were less
severe than those in the rVSVIN group, with mean severity
scores of 1.0 (minimal) and 0.5 (minimal) for rVSVIN-HIVGag5
and rVSVIN-CT1-HIVGag5, respectively (Figs. 3C, D, F, and
Table 6). These observations may have resulted from the
differences in days of necropsy; that is, viruses in macaques that
survived to day 21 may have had more opportunity to spread to
the spinal cord than those in macaques euthanized by day 8.
Fig. 2. Brain histology. Photomicrographs of hematoxylin and eosin stained sections of lateral ventricle from the thalamic region of the brain of cynomolgus macaques
following IT inoculation of: (A) wt VSVIN (macaque number 22212M) with severe periventricular inflammation and malacia, severe choroiditis, and loss of
ependymal cells; (B) rVSVIN (macaque number 21789F) with moderate periventricular inflammation; (C) rVSVIN-HIVGag5 (macaque number 22245M) with
moderate periventricular inflammation; (D) rVSVIN-CT1-HIVGag5 (macaque number 21797F) with minimal periventricular inflammation; (E) PBS (macaque
number 22238M) with no significant lesions observed; (F) rVSVIN-CT1-HIVGag5 (macaque number 21797F, higher magnification), showing characteristic
mononuclear inflammatory cell infiltrate composed primarily of lymphocytes, plasma cells, and mononuclear phagocytes along with scattered eosinophils. Black
arrow=ependyma, red arrow=denuded ependyma, black arrow head=perivascular cuffs, red arrow head=eosinophil, M=malacia, and CP=choroids plexus.
Magnification: A–E=100× and F=400×.
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6) revealed that no significant differences existed between the
PBS group, the wt group, or the two rVSV-HIV groups
(p>0.05); however, all four of these groups had significantly
lower lesion scores than the rVSVIN group (p<0.05).
Discussion
Recombinant VSV as candidate HIV vaccine vectors have
demonstrated excellent protective efficacy in SHIV challenge
studies in macaques (Egan et al., 2004; Rose et al., 2001).
However, the rVSVIN vector is both pathogenic and neurotropicin mice (Roberts et al., 1998, 1999). Therefore, we designed
exploratory studies to investigate the pathogenicity of rVSVIN
vectors in NHP prior to advancing such vectors to clinical trials.
We did not observe any vector-associated pathogenicity
following IN vaccination with the prototypic rVSVIN vector. In
the neuroinvasiveness study, neither the wt VSV nor the rVSV
vectors showed evidence of spread from nasal tissue to the
CNS. Although no virus was detected in sampled brain tissues
in any macaques at day 21, it is possible that replicating virus
did spread to neuronal tissue proximal to the inoculation site
and was simply undetectable by day 21. However, histological
analysis revealed no evidence of VSV-related neuropathology
Fig. 3. Spinal cord histology. Photomicrographs of hematoxylin and eosin stained sections of lumbar spinal cord of cynomolgus macaques following IT inoculation of:
(A) wt VSVIN (macaque number 22212M) with moderate multifocal gliosis, microhemorrhages, and mononuclear perivascular cuffs; (B) rVSVIN (macaque number
21789F) with severe multifocal coalescing gliosis and malacia, and prominent mononuclear perivascular cuffs; (C) rVSVIN-HIVGag5 (macaque number 21578F) with
marked multifocal coalescing gliosis and malacia and prominent mononuclear perivascular cuffs; (D) rVSVIN-CT1-HIVGag5 (macaque number 21576F) with
minimal focal gliosis; (E) PBS (macaque number 21724M) with no significant lesions observed; (F) rVSVIN-CT1-HIVGag5 (macaque number 21789F, higher
magnification), showing characteristic mononuclear perivascular inflammatory cell infiltrate composed primarily of lymphocytes, plasma cells, and mononuclear
phagocytes. Panels A–E: black arrow=gliosis, black arrowhead=mononuclear perivascular cuffs, white arrow=neurons, W=white matter, G=gray matter,
O=central canal of spinal cord. Panel F: Black arrow=macrophage, black arrowhead=plasma cell, white arrow=endothelial cell, and white arrowhead= lymphocyte.
Magnification: A–E=100× and F=400×.
43J.E. Johnson et al. / Virology 360 (2007) 36–49in the brains of any of the macaques inoculated IN. In a
separate study in rhesus macaques, rVSVIN was shed in nasal
secretions and saliva at low levels following IN inoculation,
and only on day 1 post-inoculation (Table 1); additionally,
there was no evidence of viremia in these macaques at any
time point after IN inoculation. Therefore, these results, as well
as those from previous studies in NHP (Egan et al., 2004,
2005; Rose et al., 2001), indicate an absence of vector-
associated pathogenicity and neuroinvasiveness for replication-
competent rVSV vectors by the IN route. The low level of
shedding at mucosal surfaces should not be a concern for early
phase clinical trials, particularly because neither vertical norhorizontal transmission of VSV is easily achieved, either
experimentally or in natural infection (Brandly and Hanson,
1957; Hanson, 1952; Reif et al., 1987; Tesh and Johnson,
1975; Webb et al., 1987).
Following IT inoculation of macaques, the wt VSVIN caused
primarily moderate to marked neuropathology, as measured by
both clinical and histological parameters. These results are
consistent with the observation that VSV is neurovirulent in
macaques (Olitsky et al., 1934) and livestock (Frank et al.,
1945) following direct intracerebral inoculation.
Of the vector groups, rVSVIN was most similar to the wt
group because one of four animals from this group displayed
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group and because all four animals had histological lesion
scores of similar severity to those in the wt group. Despite the
small numbers in each group, statistical analysis of the mean
brain lesion scores demonstrated that both the wt VSVIN group
and the rVSVIN vector groups had significantly increased lesion
scores with respect to the PBS control group, suggesting that the
rVSVIN vector is insufficiently attenuated for clinical use. The
rVSVIN-HIVGag5 and rVSVIN-CT1-HIVGag5 vectors were
significantly more attenuated than the wt and rVSVIN backbone
vector in this macaque model, particularly in the clinical
analysis, where they showed no signs of disease and were most
similar to the negative control group (Table 3). Histologically,
these two rVSV-HIV vectors caused lesions that were, on
average, less severe and more inflammatory in nature than both
the wt and rVSVIN backbone vector groups (Figs. 2 and 3, and
Table 6); the mean brain lesion scores for the rVSV-HIV vector
groups were statistically significantly lower than those of the wt
group and were not statistically significantly higher than the
PBS control group. The presence of the additional gene (HIV
Gag) and the CT1 mutation was likely responsible for the
observed attenuation of virulence.
The histology results (Table 6) indicated that the severity
scores in the wt VSVIN inoculated macaques were inconsistent
between the brain sections (mean score of 2.3) and the spinal
cord sections (mean score of 0.5). These results are most likely
due to the fact that all of the wt inoculated macaques were
euthanized at day 8, which may have been too early to allow
spread to the spinal cords. The detection of replicating virus in
occipital lobes and CSF in some macaques in this group (Table
4) suggested that spread of virus to the spinal cord occurred via
the CSF. Since the spinal cord lesion scores in the rVSVIN and
rVSVIN-HIVGag5 macaques that survived to day 21 were
higher than those in the wt group (Table 6), which were all
euthanized by day 8, it apparently required more than 8 days for
virus to cause spinal cord lesions. We have observed a similar
phenomenon in mice inoculated intracranially with the wt and
rVSVIN-CT1 viruses; the wt virus killed the mice so rapidly that
their brain lesion scores were lower than those in the rVSVIN-
CT1 inoculated mice that survived longer (unpublished results).
It is also possible that slight variations in the inoculation
procedure may have resulted in variation in the immediate
distribution of the inoculum, with some macaques having
increased initial contamination of the CSF with the virus and
consequently increased neuropathology in sites distal to the
injection site.
Histological evidence of neuropathology was not clearly
reflected by clinical or virological parameters. For example,
macaques in the rVSVIN-HIVGag5 and rVSVIN-CT1-HIV-
Gag5 groups had clinical scores similar to the negative
control group, and there was no detectable virus or viral RNA
in tissues at day 21. However, the histological analysis of
brain and spinal cord tissue indicated that productive infection
had occurred in these macaques, causing lesions that were
mostly minimal, but were moderate to marked in some tissues
in some macaques (Table 6). Similar results were observed in
the three macaques in the rVSVIN group that survived to day21, in which the lack of clinical signs or detectable virus did
not coincide with the relatively high lesion scores in brains
and spinal cords. Therefore, the histological analysis appeared
to be the more sensitive means of assessing NV in this model,
as is the case in NHP NV tests of yellow fever and mumps
vaccines (Levenbook et al., 1987; Maximova et al., 1996;
Rubin et al., 1999). Furthermore, the viral load measurements
were best suited to time points when viral replication
occurred, as observed in the macaques that died or were
euthanized by day 8. Based on the collective infectivity and
RT-PCR data, it is clear that the wt virus and rVSVIN
backbone vector replicated at early time points following
inoculation and that detectable replication had ceased in all
groups by day 21. Presumably, the rVSVIN-HIVGag5 and
rVSVIN-CT1-HIVGag5 viruses also replicated at early time
points because there was serologic evidence of viral
replication (Table 2). Although some of the macaques
inoculated with rVSVIN-CT1-HIVGag5 did not raise detect-
able neutralizing antibodies, the virus likely was able to
establish an infection at the site of inoculation. It has
previously been demonstrated in mice that the rVSVIN-CT1
vector generated low levels of antibodies after a single IN
inoculation and that boosting was required to achieve high
levels of anti-VSV neutralizing antibodies (Roberts et al.,
1999). Subsequent studies in the NHP NV model should
include sampling CNS tissues at earlier time points to more
accurately measure viral replication within these tissues.
Regulatory agencies have historically required NV testing
for live viral vaccines. In the case of yellow fever and mumps
vaccines, both of which were originally approved under
different, early regulatory standards, the vaccine strains must
show a significant decrease in histopathology if the reference
control is a wild type strain, or no significant increase in
histopathology if the reference control is a vaccine strain. In this
study, HIV vaccine candidates rVSVIN-HIVGag5 and rVSVIN-
CT1-HIVGag5 generated histopathology severity scores that
were not statistically different from those of the PBS group and
that were statistically lower than those of the wt group.
However, increased regulatory stringency and a lack of
established safety record for rVSV vectors in humans as
compared to such vaccines as measles, mumps, polio, and
yellow fever (Arya, 2002) remain concerns for developing
rVSV vectors as vaccine candidates. Therefore, we have
proceeded to construct additional, further attenuated rVSV
vector candidates [reviewed in Clarke et al., 2006] using such
approaches as gene rearrangement (Ball et al., 1999; Flanagan et
al., 2001, 2003; Novella et al., 2004; Wertz et al., 1998),
ablation of expression of the M2 and M3 polypeptides encoded
by the M gene (Jayakar and Whitt, 2002), temperature sensitive
mutations (Flamand and Pringle, 1971; Pringle, 1970), and gene
deletions or truncations (Jeetendra et al., 2003; Kahn et al.,
2001; Roberts et al., 1999; Robison and Whitt, 2000).
There is an additional concern regarding the utility of
the macaque model for rVSV NV testing. In this model,
there was no statistically significant difference between the
histological scores in the rVSVIN-HIVGag5 and rVSVIN-
CT1-HIVGag5 groups (Table 6) despite the fact that the
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vitro and in mice following IN inoculation (Roberts et al.,
1999; Schnell et al., 1998). In addition, the wt VSVIN
caused severe clinical illness that required euthanasia of
macaques inoculated IT by day 8, which complicated the
comparisons to other groups in which the macaques survived
to day 21. The NHP NV model for VSV therefore requires
additional development. Because of cost and procurement
issues associated with NHP, we also intend to investigate
alternate animal models for testing rVSV vector-associated
pathogenicity.
Materials and methods
Viruses and vectors tested in NHP studies
The viruses tested in these studies included tissue culture-
adapted wt VSVIN; the prototypic, attenuated vector rVSVIN;
the rVSVIN vector encoding HIV Gag protein; and a further
attenuated vector encoding HIV Gag, rVSVIN-CT1-HIVGag5
(Fig. 1). The tissue culture-adapted San Juan isolate of VSV
Indiana serotype (wt VSVIN) was least attenuated in vitro and
was highly pathogenic in mice (Roberts et al., 1998). The
rVSVIN was derived from a cDNA encoding the entire genome
of VSVIN (Lawson et al., 1995), which was constructed using
RT-PCR products combined from the genomes of VSVIN, San
Juan and Mudd-Summers isolates. The resulting virus contained
multiple nucleotide sequence differences from the parental San
Juan isolate that presumably accounted for the in vivo
attenuation of rVSVIN relative to wt VSVIN (Roberts et al.,
1998). This cDNA served as the “backbone” vector from which
the two rVSV-HIV vectors were derived. The prototypic HIV
vaccine vector, rVSVIN-HIVGag5, was similar to the vectors
tested previously in SHIV challenge studies in macaques (Rose
et al., 2001), except that this vector encoded an HIV-1 Gag
protein rather than an SIV Gag. Finally, the rVSVIN-CT1-
HIVGag5 contained a mutant G gene that encodes a protein in
which the cytoplasmic tail domain is truncated from 29 amino
acids to a single amino acid (CT1); this mutation has been
shown to greatly reduce vector pathogenicity in mice following
IN inoculation (Roberts et al., 1999; Schnell et al., 1998). Since
PBS was the diluent for each virus, it was used as the negative
control inoculum.
The wild type, rVSVIN, and rVSVIN-CT1-HIVGag5 viruses
were provided by Dr. John K. Rose (Yale University, New
Haven, CT). The rVSVIN-HIVGag5 virus was rescued from
cDNA pVSVIN-HIVGag5 using standard reverse genetics
procedures (Lawson et al., 1995; Schnell et al., 1996b). The
cDNA pVSVIN-HIVGag5 was generated by PCR amplification
of the ORF of the HIV-1 gag gene (HXB2 strain) and insertion
into the VSV vector backbone pVSV-XN1 (Schnell et al.,
1996b) via XhoI and NheI restriction sites as the fifth gene in
the genome. All viruses were amplified on baby hamster kidney
(BHK) cells at a multiplicity of infection (MOI) between 0.1
and 1, concentrated by ultracentrifugation through 10% sucrose
(28,000 rpm in a Beckman SW28 rotor at 4 °C for 75–90 min)
and resuspended in phosphate buffered saline (PBS).Viral shedding study in rhesus macaques
The rhesus macaque study was performed at the University
of Louisiana at Lafayette-New Iberia Research Center (New
Iberia), LA, with adherence to the regulations outlined in the
USDA Animal Welfare Act (9 CFR, parts 1, 2 and 3) and the
conditions specified in the Guide for the Care and Use of
Laboratory Animals (ILAR publication, 1996, National Acad-
emy Press). Any clinical signs of illness or distress were
promptly reported to the responsible veterinarian, who
recommended either treatment for minor ailments and injuries
or euthanasia for profound effects such as severe emesis or
convulsions.
Because of limited availability of macaques, three male
rhesus macaques (3–4 years old) were vaccinated, and two un-
inoculated macaques served as negative controls (Fig. 1A).
Following light sedation with ketamine, macaques were
inoculated IN with a total of 107 plaque-forming units (PFU)
of rVSVIN in PBS, delivered to both nostrils in a total of
0.8 mL by micropipettor. Samples were collected as follows:
saliva and nasal washes (in that order, ≥1.0 mL each) on days
1–4, 6, 8, 10, 13, 16, 19, and 22; serum (1.0 mL) pre-dose and
on days 1–4, 8, 13, and 22; whole blood (including sodium
heparin as an anti-coagulant, 10 mL) pre-dose and on days 8,
14, and 22.
Neuroinvasiveness and neurovirulence (NV) studies in
cynomolgus macaques
Both the NV and neuroinvasiveness studies were performed
at Charles River Laboratories, Inc.-Preclinical Services (Sparks,
NV). The cynomolgus macaque studies adhered to the
regulations outlined in the USDA Animal Welfare Act (9
CFR, Parts 1, 2, and 3) and the conditions specified in the Guide
for the Care and Use of Laboratory Animals (ILAR publication,
1996, National Academy Press). Any clinical signs of illness or
distress were promptly reported to the responsible veterinarian,
who recommended either treatment for minor ailments and
injuries or euthanasia for profound effects such as severe emesis
or convulsions.
Cynomolgus macaques (2–3.5 years old) were inocu-
lated either intranasally (IN) or intrathalamically (IT) with
a total of 107 PFU of virus per macaque (Fig. 1B). Each
group contained two females and two males. For IN
inoculations, macaques were lightly sedated with ketamine.
Each macaque received a total of 1.0 mL of inoculum,
injected via syringe into both nostrils over the course of
approximately 1 min. Non-anti-inflammatory analgesics
were given at the discretion of the veterinarian to prevent
post-inoculation discomfort.
For IT inoculations, macaques were anesthetized with a
mixture of ketamine and valium; each macaque's head was
shaved, and incisions were made through the skin at
approximately 1.5 cm on either side of the sagittal suture
and at approximately 0.5 cm from the coronal suture of the
head of the macaque. A high-speed, general twist drill was
used to make two 0.16 cm holes through the skull,
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Subsequently, 0.1 mL of the virus or control inoculum was
injected into the right and left thalamic regions for a total dose
volume of 0.2 mL/macaque, using a 25 gauge×1 1/2 in.
needle (to a depth of approximately 1 in.) on a 1.0 mL
tuberculin syringe, introduced in a medial–oral direction.
After inoculation, the surgical area was closed with a
subcuticular suture to minimize self-inflicted trauma by the
macaque. Each macaque was observed until it recovered from
anesthesia and was then returned to its cage. Non-anti-
inflammatory analgesics were given at the discretion of the
veterinarian to prevent post-surgical discomfort.
Macaques were monitored for 21 days after challenge for
the following parameters: food consumption, body weight and
temperature, serum chemistry, hematology, and general clinical
parameters, the latter of which were scored using a system
based on that used for yellow fever vaccine (Levenbook et al.,
1987). Macaques were examined twice daily for possible
clinical signs of encephalitis and were assigned numerical
scores as follows: 0, no clinical signs of encephalitis; 1, rough
coat, not eating; 2, high pitched voice, inactive, slow moving;
3, shaky movements, tremors, incoordination, limb weakness;
4, inability to stand, limb paralysis, moribundity, or death. The
higher of the two daily individual macaque scores was
assigned as the daily score. The mean daily clinical score for
each macaque was calculated by averaging the 22 individual
macaque daily scores, and the group mean daily scores were
calculated for each study day by averaging the individual
macaque scores for each group. At the time of euthanasia
(scheduled or unscheduled), the macaques were exsanguinated
while under deep anesthesia induced with ketamine and
Beuthanasia®-D.
Tissue preparation
All tissues and fluids were collected at the time of
euthanasia. For quantification of virus, frozen samples of
occipital and frontal cortex were thawed, weighed, and
suspended in PBS supplemented with 1× sucrose, phosphate,
glutamate buffer (0.2 M sucrose, 7.0 mM K2HPO4, 3.8 mM
KH2PO4, 5.0 mM glutamic acid) to generate 10% (w:v) tissue
suspensions. Samples were homogenized using an Omni Mixer
ES with aerosol-sealed stainless steel chambers (Omni Interna-
tional). Tissue homogenates were centrifuged at 3000 rpm for
15 min at 4 °C and clarified supernatants used immediately for
plaque assay or RT-PCR, as described below. Cerebral spinal
fluid (CSF) samples were thawed and used directly in assays.
PBMCs were assayed for the presence of infectious VSV by
two methods: direct co-culture of the PBMCs with BHKs or
following a freeze–thaw and clarification of the lysates.
Histopathological evaluation
Brain and spinal cord tissue sections were collected from
each macaque (following gross necropsy) and fixed in neutral
buffered 10% formalin. Samples were taken from five brain
regions (Fig. 1C) including frontal cortex, occipital cortex,cerebellum, thalamus, basal ganglia, and from three spinal cord
regions (cervical, thoracic, and lumbar). Fixed tissues were
mounted onto slides and stained with eosin and hematoxylin for
histological examinations, which were performed by Roger
Price, D.V.M., Ph.D., D.A.C.V.P. (Veterinary Pathology
Services, Houston, TX), and peer-reviewed by Andrew Lackner,
D.V.M., D.A.C.V.P. (Tulane National Primate Research Center,
Covington, LA) and Mary E.P. Goad, D.V.M., Ph.D. (Explora-
tory Drug Safety, Wyeth Research, Andover, MA).
Plaque assay
Ten-fold serial dilutions of tissue homogenates, PBMCs,
PBMC lysates, or CSF were prepared in Dulbecco's Modified
Eagle Medium (DMEM, Mediatech, Inc.) with 10% fetal
bovine serum (FBS). Aliquots (100 μL) of each dilution were
placed on confluent BHK or Vero cell monolayers in 6-well
plates and allowed to absorb for 15 min at room temperature
followed by incubation at 37 °C for 30 min. Inoculum was
removed from each well, which was then overlaid with 0.8%
agarose in DMEM+10% FBS. Plates were incubated at 37 °C
overnight. Agar overlays were removed, and plates were stained
for 10–20 min at room temperature with 2 mL/well of crystal
violet stain solution (1% crystal violet in 70% methanol).
Real-time quantitative RT-PCR
Aliquots of tissue homogenates (500 μL) were centrifuged at
14,000 rpm for 5 min. Viral RNA was extracted from clarified
supernatants or CSF samples (140 μL) using QIAamp Viral
Mini Kit (Qiagen, Inc.). An equivalent volume of buffer was
extracted as a negative control, and an aliquot of the viral
inoculum was extracted as a positive control.
Using Primer Express software (PE Applied Biosystems),
primers (Qiagen) and probe (AB Applied Biosystems) for the
VSV N gene were designed to amplify a 70-nucleotide
fragment. The sequence of the forward primer was as follows:
5′-GATAGTACCGGAGGATTGACGACTA-3′ corresponding
to nucleotide positions 1075–1099 in the N open reading frame.
The reverse primer sequence was as follows: 5′-AACCATCC-
GAGCCATTCGA-3′ corresponding to nucleotide positions
1127–1145 in the N open reading frame. The fluorogenic
probe was labeled at the 5′ end with the reporter dye
6-carboxyfluorescein (FAM) and at the 3′ end with the quencher
dye 6-carboxytetramethylrhodamine (TAMRA), and its se-
quence was as follows: 5′-TGCACCGCCACAAGGCA-
GAGA-3′ corresponding to nucleotide positions 1101–1121 in
the N open reading frame.
To determine the number of genome copies of VSV, a
synthetic RNA oligonucleotide corresponding to the entire
amplified region was synthesized and PAGE-purified (TriLink
BioTechnologies). Following precipitation and centrifugation,
the number of oligonucleotide copies per μL of solution was
calculated using Avogadro's number, the molecular weight, and
the extinction coefficient of the oligonucleotide. Serial 10-fold
dilutions were made of this synthetic oligonucleotide and used
to generate a standard curve.
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step procedure to detect the genomic (negative sense) RNA of
VSV. The initial reaction mixture for reverse transcription
(25 μL) contained 7.5 μL purified RNA, 900 nM forward
primer, reagents from the TaqMan® Reverse Transcription
Reagents kit (Applied Biosystems), and 15 units/μL of
ThermoScript™ Reverse Transcriptase (InVitrogen™ Life
Technologies). The reaction was incubated at 60 °C for
30 min, which was followed by an inactivation step of heating
at 95 °C for 15 min. Then, 30 μL of 2× Master mix buffer
(TaqMan® One Step PCR Master Mix Reagent Kit; Applied
Biosystems), 900 nM of reverse primer, and 200 nM of probe
was added to the cDNA reaction mix to bring the final volume
to 60 μL. Amplification and detection were performed with an
ABI Prism 7700 Sequence Detection System under the
following conditions: 10 min at 95 °C, and 40 cycles of
15 s at 95 °C and 1 min at 60 °C. All samples were tested in
duplicate.
VSV serum neutralization assay
Sera were diluted with PBS in a volume of 50 μL in serial
two-fold dilutions in 96-well plates. One hundred PFU of virus
(rVSVIN) in 50 μL of serum-free DMEM was added to each
well. Plates containing serum and virus were incubated at 37 °C
for 1 h. Approximately 1500 BHK cells in 100 μL of DMEM–
10% FBS were then added to each well. The plates were
incubated at 37 °C and 5% CO2 for 2 to 3 days and assayed by
microscopy for the presence of VSV-induced cytopathology.
Each assay was performed in duplicate. Neutralizing titers were
assigned as the highest dilutions that completely inhibited VSV-
induced cytopathology.
Statistical analysis
Differences in histopathological scores among groups of
macaques were analyzed by one-way analysis of variance using
the Dunnett multiple comparisons post test (InStat version 2.02,
GraphPad Software, San Diego, CA).
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